Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Depreciation & Amortization (CF): 2013-2024

Historic Depreciation & Amortization (CF) for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to $5.5 million.

  • Seres Therapeutics' Depreciation & Amortization (CF) fell 25.64% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 29.11%. This contributed to the annual value of $5.5 million for FY2024, which is 12.41% down from last year.
  • As of FY2024, Seres Therapeutics' Depreciation & Amortization (CF) stood at $5.5 million, which was down 12.41% from $6.2 million recorded in FY2023.
  • Over the past 5 years, Seres Therapeutics' Depreciation & Amortization (CF) peaked at $6.6 million during FY2022, and registered a low of $5.5 million during FY2024.
  • Over the past 3 years, Seres Therapeutics' median Depreciation & Amortization (CF) value was $6.2 million (recorded in 2023), while the average stood at $6.1 million.
  • Per our database at Business Quant, Seres Therapeutics' Depreciation & Amortization (CF) decreased by 13.48% in 2020 and then rose by 11.47% in 2022.
  • Over the past 5 years, Seres Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $6.6 million in 2020, then declined by 9.59% to $5.9 million in 2021, then climbed by 11.47% to $6.6 million in 2022, then dropped by 5.82% to $6.2 million in 2023, then decreased by 12.41% to $5.5 million in 2024.